Global Nonalcoholic Steatohepatitis (NASH) Market Research Report 2021
- Published Date: 2021-04-20
- Report ID: 101550
- Pages: 180
-
Format:
Prudent Markets Predicts that Nonalcoholic Steatohepatitis (NASH) Market was valued USD xxxx unit in 2020 and is expected to reach USD xxxx Unit by the year 2025, growing at a CAGR of xx% globally.
Global Nonalcoholic Steatohepatitis (NASH) Market Overview:
Global Nonalcoholic Steatohepatitis (NASH) Market Report 2020 comes with the extensive industry analysis of development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2020-2025.This research study of Nonalcoholic Steatohepatitis (NASH) involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Impact of COVID-19 on Nonalcoholic Steatohepatitis (NASH) Market
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost every country around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affected the Nonalcoholic Steatohepatitis (NASH) market in 2020.
Global Nonalcoholic Steatohepatitis (NASH) Market Segmentation
By Type, Nonalcoholic Steatohepatitis (NASH) market has been segmented into:
Weight Loss Treatment
Insulin-Sensitizing Agents
Lipid-Lowering Drugs
Antioxidants
Others
By Application, Nonalcoholic Steatohepatitis (NASH) market has been segmented into:
Hospitals
Clinics
Research Institute
Others
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain etc.)
Asia-Pacific (China, India, Japan, Southeast Asia etc.)
South America (Brazil, Argentina etc.)
Middle East & Africa (Saudi Arabia, South Africa etc.)
Top Key Players Covered in Nonalcoholic Steatohepatitis (NASH) market are:
Boehringer Ingelheim
Cerenis Therapeutics
Connexios Life Sciences
Genfit
Islet Sciences
Nimbus Therapeutics
Verva Pharmaceuticals
Viking Therapeutics
Astazeneca Plc
Galmed Pharmaceuticals
GENFIT SA
Gilead Science
Novo Nordisk
Immuron
Intercepts Pharmaceuticals
Enzo Biochem
Tobira Therapeutics
1. Market Overview of Nonalcoholic Steatohepatitis (NASH)
1.1 Nonalcoholic Steatohepatitis (NASH) Market Overview
1.1.1 Nonalcoholic Steatohepatitis (NASH) Product Scope
1.1.2 Market Status and Outlook
1.2 Nonalcoholic Steatohepatitis (NASH) Market Size by Regions: 2015 VS 2021 VS 2026
1.3 Nonalcoholic Steatohepatitis (NASH) Historic Market Size by Regions (2015-2020)
1.4 Nonalcoholic Steatohepatitis (NASH) Forecasted Market Size by Regions (2021-2026)
1.5 Covid-19 Impact on Key Regions, Keyword Market Size YoY Growth (2015-2026)
1.5.1 North America
1.5.2 East Asia
1.5.3 Europe
1.5.4 South Asia
1.5.5 Southeast Asia
1.5.6 Middle East
1.5.7 Africa
1.5.8 Oceania
1.5.9 South America
1.5.10 Rest of the World
1.6 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
1.6.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
1.6.2 Covid-19 Impact: Commodity Prices Indices
1.6.3 Covid-19 Impact: Global Major Government Policy
2. Covid-19 Impact Nonalcoholic Steatohepatitis (NASH) Sales Market by Type (2015-2026)
2.1 Global Nonalcoholic Steatohepatitis (NASH) Historic Market Size by Type (2015-2020)
2.2 Global Nonalcoholic Steatohepatitis (NASH) Forecasted Market Size by Type (2021-2026)
2.3 Weight Loss Treatment
2.4 Insulin-Sensitizing Agents
2.5 Lipid-Lowering Drugs
2.6 Antioxidants
2.7 Others
3. Covid-19 Impact Nonalcoholic Steatohepatitis (NASH) Sales Market by Application (2015-2026)
3.1 Global Nonalcoholic Steatohepatitis (NASH) Historic Market Size by Application (2015-2020)
3.2 Global Nonalcoholic Steatohepatitis (NASH) Forecasted Market Size by Application (2021-2026)
3.3 Hospitals
3.4 Clinics
3.5 Research Institute
3.6 Others
4. Covid-19 Impact Market Competition by Manufacturers
4.1 Global Nonalcoholic Steatohepatitis (NASH) Production Capacity Market Share by Manufacturers (2015-2020)
4.2 Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share by Manufacturers (2015-2020)
4.3 Global Nonalcoholic Steatohepatitis (NASH) Average Price by Manufacturers (2015-2020)
5. Company Profiles and Key Figures in Nonalcoholic Steatohepatitis (NASH) Business
5.1 Boehringer Ingelheim
5.1.1 Boehringer Ingelheim Company Profile
5.1.2 Boehringer Ingelheim Nonalcoholic Steatohepatitis (NASH) Product Specification
5.1.3 Boehringer Ingelheim Nonalcoholic Steatohepatitis (NASH) Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.2 Cerenis Therapeutics
5.2.1 Cerenis Therapeutics Company Profile
5.2.2 Cerenis Therapeutics Nonalcoholic Steatohepatitis (NASH) Product Specification
5.2.3 Cerenis Therapeutics Nonalcoholic Steatohepatitis (NASH) Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.3 Connexios Life Sciences
5.3.1 Connexios Life Sciences Company Profile
5.3.2 Connexios Life Sciences Nonalcoholic Steatohepatitis (NASH) Product Specification
5.3.3 Connexios Life Sciences Nonalcoholic Steatohepatitis (NASH) Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.4 Genfit
5.4.1 Genfit Company Profile
5.4.2 Genfit Nonalcoholic Steatohepatitis (NASH) Product Specification
5.4.3 Genfit Nonalcoholic Steatohepatitis (NASH) Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.5 Islet Sciences
5.5.1 Islet Sciences Company Profile
5.5.2 Islet Sciences Nonalcoholic Steatohepatitis (NASH) Product Specification
5.5.3 Islet Sciences Nonalcoholic Steatohepatitis (NASH) Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.6 Nimbus Therapeutics
5.6.1 Nimbus Therapeutics Company Profile
5.6.2 Nimbus Therapeutics Nonalcoholic Steatohepatitis (NASH) Product Specification
5.6.3 Nimbus Therapeutics Nonalcoholic Steatohepatitis (NASH) Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.7 Verva Pharmaceuticals
5.7.1 Verva Pharmaceuticals Company Profile
5.7.2 Verva Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product Specification
5.7.3 Verva Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.8 Viking Therapeutics
5.8.1 Viking Therapeutics Company Profile
5.8.2 Viking Therapeutics Nonalcoholic Steatohepatitis (NASH) Product Specification
5.8.3 Viking Therapeutics Nonalcoholic Steatohepatitis (NASH) Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.9 Astazeneca Plc
5.9.1 Astazeneca Plc Company Profile
5.9.2 Astazeneca Plc Nonalcoholic Steatohepatitis (NASH) Product Specification
5.9.3 Astazeneca Plc Nonalcoholic Steatohepatitis (NASH) Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.10 Galmed Pharmaceuticals
5.10.1 Galmed Pharmaceuticals Company Profile
5.10.2 Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product Specification
5.10.3 Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.11 GENFIT SA
5.11.1 GENFIT SA Company Profile
5.11.2 GENFIT SA Nonalcoholic Steatohepatitis (NASH) Product Specification
5.11.3 GENFIT SA Nonalcoholic Steatohepatitis (NASH) Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.12 Gilead Science
5.12.1 Gilead Science Company Profile
5.12.2 Gilead Science Nonalcoholic Steatohepatitis (NASH) Product Specification
5.12.3 Gilead Science Nonalcoholic Steatohepatitis (NASH) Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.13 Novo Nordisk
5.13.1 Novo Nordisk Company Profile
5.13.2 Novo Nordisk Nonalcoholic Steatohepatitis (NASH) Product Specification
5.13.3 Novo Nordisk Nonalcoholic Steatohepatitis (NASH) Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.14 Immuron
5.14.1 Immuron Company Profile
5.14.2 Immuron Nonalcoholic Steatohepatitis (NASH) Product Specification
5.14.3 Immuron Nonalcoholic Steatohepatitis (NASH) Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.15 Intercepts Pharmaceuticals
5.15.1 Intercepts Pharmaceuticals Company Profile
5.15.2 Intercepts Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product Specification
5.15.3 Intercepts Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.16 Enzo Biochem
5.16.1 Enzo Biochem Company Profile
5.16.2 Enzo Biochem Nonalcoholic Steatohepatitis (NASH) Product Specification
5.16.3 Enzo Biochem Nonalcoholic Steatohepatitis (NASH) Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.17 Tobira Therapeutics
5.17.1 Tobira Therapeutics Company Profile
5.17.2 Tobira Therapeutics Nonalcoholic Steatohepatitis (NASH) Product Specification
5.17.3 Tobira Therapeutics Nonalcoholic Steatohepatitis (NASH) Production Capacity, Revenue, Price and Gross Margin (2015-2020)
6. North America
6.1 North America Nonalcoholic Steatohepatitis (NASH) Market Size (2015-2026)
6.2 North America Nonalcoholic Steatohepatitis (NASH) Key Players in North America (2015-2020)
6.3 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2015-2020)
6.4 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2015-2020)
7. East Asia
7.1 East Asia Nonalcoholic Steatohepatitis (NASH) Market Size (2015-2026)
7.2 East Asia Nonalcoholic Steatohepatitis (NASH) Key Players in North America (2015-2020)
7.3 East Asia Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2015-2020)
7.4 East Asia Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2015-2020)
8. Europe
8.1 Europe Nonalcoholic Steatohepatitis (NASH) Market Size (2015-2026)
8.2 Europe Nonalcoholic Steatohepatitis (NASH) Key Players in North America (2015-2020)
8.3 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2015-2020)
8.4 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2015-2020)
9. South Asia
9.1 South Asia Nonalcoholic Steatohepatitis (NASH) Market Size (2015-2026)
9.2 South Asia Nonalcoholic Steatohepatitis (NASH) Key Players in North America (2015-2020)
9.3 South Asia Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2015-2020)
9.4 South Asia Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2015-2020)
10. Southeast Asia
10.1 Southeast Asia Nonalcoholic Steatohepatitis (NASH) Market Size (2015-2026)
10.2 Southeast Asia Nonalcoholic Steatohepatitis (NASH) Key Players in North America (2015-2020)
10.3 Southeast Asia Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2015-2020)
10.4 Southeast Asia Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2015-2020)
11. Middle East
11.1 Middle East Nonalcoholic Steatohepatitis (NASH) Market Size (2015-2026)
11.2 Middle East Nonalcoholic Steatohepatitis (NASH) Key Players in North America (2015-2020)
11.3 Middle East Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2015-2020)
11.4 Middle East Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2015-2020)
12. Africa
12.1 Africa Nonalcoholic Steatohepatitis (NASH) Market Size (2015-2026)
12.2 Africa Nonalcoholic Steatohepatitis (NASH) Key Players in North America (2015-2020)
12.3 Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2015-2020)
12.4 Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2015-2020)
13. Oceania
13.1 Oceania Nonalcoholic Steatohepatitis (NASH) Market Size (2015-2026)
13.2 Oceania Nonalcoholic Steatohepatitis (NASH) Key Players in North America (2015-2020)
13.3 Oceania Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2015-2020)
13.4 Oceania Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2015-2020)
14. South America
14.1 South America Nonalcoholic Steatohepatitis (NASH) Market Size (2015-2026)
14.2 South America Nonalcoholic Steatohepatitis (NASH) Key Players in North America (2015-2020)
14.3 South America Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2015-2020)
14.4 South America Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2015-2020)
15. Rest of the World
15.1 Rest of the World Nonalcoholic Steatohepatitis (NASH) Market Size (2015-2026)
15.2 Rest of the World Nonalcoholic Steatohepatitis (NASH) Key Players in North America (2015-2020)
15.3 Rest of the World Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2015-2020)
15.4 Rest of the World Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2015-2020)
16 Nonalcoholic Steatohepatitis (NASH) Market Dynamics
16.1 Covid-19 Impact Market Top Trends
16.2 Covid-19 Impact Market Drivers
16.3 Covid-19 Impact Market Challenges
16.4 Porters Five Forces Analysis
18 Regulatory Information
17 Analyst's Viewpoints/Conclusions
18 Appendix
18.1 Research Methodology
18.1.1 Methodology/Research Approach
18.1.2 Data Source
18.2 Disclaimer
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
